CHA₂DS₂-VASc Score Calculation and Anticoagulation Recommendations
For patients with atrial fibrillation, calculate the CHA₂DS₂-VASc score (or CHA₂DS₂-VA score per 2024 ESC guidelines) and initiate oral anticoagulation with a DOAC for scores ≥2, consider anticoagulation for score of 1, and withhold anticoagulation only for score of 0. 1
Score Calculation
The CHA₂DS₂-VASc score assigns points as follows 2, 1:
- C (Congestive heart failure/LV dysfunction): 1 point
- Symptoms/signs of heart failure regardless of LVEF, OR asymptomatic LVEF ≤40%
- H (Hypertension): 1 point
- BP >140/90 mmHg on ≥2 occasions OR current antihypertensive treatment
- A₂ (Age ≥75 years): 2 points
- D (Diabetes mellitus): 1 point
- Type 1 or 2, or glucose-lowering therapy
- S₂ (Prior Stroke/TIA/thromboembolism): 2 points
- V (Vascular disease): 1 point
- Coronary artery disease (MI, angina, revascularization, significant CAD on imaging)
- A (Age 65-74 years): 1 point
- Sc (Sex category - Female): 1 point
Maximum score: 9 points
Important Update: CHA₂DS₂-VA Score
The 2024 ESC guidelines now recommend CHA₂DS₂-VA (removing female sex as a risk factor), as recent evidence shows female sex alone does not independently increase stroke risk 1, 3. The predictive performance is equivalent between the two scores 3.
Anticoagulation Recommendations by Score
Score = 0 (Truly Low Risk)
- No anticoagulation required 1
- Annual stroke rate: 0.04-0.84% 2, 4
- Antiplatelet therapy is NOT recommended as alternative 1
Score = 1 (Intermediate Risk)
- Oral anticoagulation should be considered (Class IIa recommendation) 1
- Annual stroke rate: 0.55-1.79% 2, 4
- All subgroups within CHA₂DS₂-VASc 1 (hypertension alone, heart failure alone, diabetes alone, vascular disease alone, age 65-74 alone) carry similar risk 5
- Shared decision-making is critical at this threshold
Score ≥2 (High Risk)
- Oral anticoagulation is recommended (Class I) 1
- Annual stroke rate increases progressively: 0.83% (score 2) to 6.62% (score 9) 2
- Score of 3: 1.66-3.72% annual stroke rate
- Score of 4: 2.80-4.31% annual stroke rate
- Score ≥5: >4.3% annual stroke rate
Choice of Anticoagulant
Direct Oral Anticoagulants (DOACs) are preferred over warfarin 1:
- Apixaban, dabigatran, edoxaban, or rivaroxaban
- Exceptions: mechanical heart valves and mitral stenosis (use warfarin)
DOAC Dosing 2:
- Apixaban: 5 mg twice daily (reduce to 2.5 mg twice daily if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Rivaroxaban: 20 mg once daily with largest meal (15 mg if CrCl 15-50 mL/min)
- Edoxaban: 60 mg once daily (30 mg if CrCl 15-50 mL/min, weight ≤60 kg, or certain P-glycoprotein inhibitors)
- Dabigatran: 150 mg twice daily (75 mg twice daily if CrCl 15-30 mL/min)
Warfarin Dosing:
- Target INR 2.0-3.0
- Time in therapeutic range should be >70% 1
Special Populations
High-Risk Conditions Requiring Anticoagulation Regardless of Score:
- Hypertrophic cardiomyopathy: Anticoagulate regardless of CHA₂DS₂-VASc 1
- Cardiac amyloidosis: Anticoagulate regardless of CHA₂DS₂-VASc 1
Subclinical/Device-Detected AF:
- For CHA₂DS₂-VASc >4: Strong net benefit with apixaban (prevents 1.28 strokes per 100 patient-years, causes 0.68 major bleeds) 6
- For CHA₂DS₂-VASc <4: Risks may outweigh benefits 6
- May consider DOAC therapy (Class IIb) 1
Cancer Patients:
- CHA₂DS₂-VASc score remains valid but shows higher odds ratios for stroke at each score level 7
- Emphasizes importance of anticoagulation initiation in this population
Critical Pitfalls to Avoid
- Do not use aspirin as stroke prophylaxis - it is ineffective and not recommended 1
- Reassess risk periodically - scores change over time as patients age and develop comorbidities 1
- Do not withhold anticoagulation based on bleeding risk scores alone - manage modifiable bleeding risk factors instead 1
- Avoid combining anticoagulants with antiplatelets unless acute vascular event or procedural indication 1
- Switch from warfarin to DOAC if intracranial hemorrhage risk or poor INR control 1